Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
24,683,081

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie

Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate

by Zacks Equity Research

Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.

Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration

by Zacks Equity Research

Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.

Pfizer Begins Pivotal Study on Alopecia Areata Candidate

by Zacks Equity Research

Pfizer (PFE) initiates a pivotal phase IIb/III study to evaluate JAK3 inhibitor, PF-06651600, for treating moderate to severe alopecia areata.

Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019?

by Zacks Equity Research

Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $42.97, moving +0.28% from the previous trading session.

Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

by Zacks Equity Research

Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.

Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?

by Zacks Equity Research

Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.

Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study

by Zacks Equity Research

Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months.

AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib

by Zacks Equity Research

AbbVie (ABBV) submits regulatory applications in the United States and EU for upadacitinib, for the treatment of adult patients with moderate to severe rheumatoid arthritis.

Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study

by Zacks Equity Research

Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.

Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations

by Zacks Equity Research

Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.

Company News For Dec 20, 2018

by Zacks Equity Research

Companies In The News Are: FDX,GIS,LLY,PFE,GSK

Glaxo, Pfizer to Merge Consumer Health Units, Form New JV

by Zacks Equity Research

Glaxo (GSK) and Pfizer agree to merge their consumer healthcare units into a new joint venture (JV) with almost $13 billion in annual sales. Glaxo will eventually spin-off the joint venture.

Do Options Traders Know Something About Pfizer (PFE) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Adobe, Johnson & Johnson and IBM

Mark Vickery headshot

Top Research Reports for Walmart, Pfizer & Adobe

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Adobe (ADBE).

Pfizer (PFE) Stock Moves -1.58%: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $43.11, marking a -1.58% move from the previous day.

Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod

by Zacks Equity Research

Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).

Lilly (LLY) to Acquire Pain Candidate From Private Biotech

by Zacks Equity Research

Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

Sweta Killa headshot

Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?

by Sweta Killa

Smart Beta ETF report for FLQL

Pfizer's (PFE) Shares Drop on Rating Downgrade by JP Morgan

by Zacks Equity Research

JP Morgan downgrades Pfizer (PFE) on assumptions that the market has discounted all growth factors for Pfizer.